BioWorld

Sep. 21, 2007

Peramivir Stumbles In Phase II Influenza Study; BioCryst Falls

Shares of BioCryst Pharmaceuticals Inc. tumbled more than 30 percent following a Phase II miss with the influenza drug peramivir, despite assurances from company executives that inadequate needle-lengths were to blame. (BioWorld Today) Read More

House Passes Long-Awaited Legislation On FDA Reform

NewCo News: ImmunoBiosciences Using ICV Platform To Improve Vaccines

Progenics Raises $57M Publicly; Cellerix Gets $40M In Series B

Other News To Note

ICAAC Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 27, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...